Tammie Payne
Family · Everett, PANPI 1174084339
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (35.2%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 47.8% of the total. Reporting peaked in 2024 at $11,669 and has fallen 57.9% since, to $4,917 in 2025. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $140.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$12K
- Embecta Corp.$3K
- Mannkind Corporation$2K
- Novo Nordisk$961
- BD$821
- Tandem Diabetes Care, Inc.$775
- plus $6K from 26 others
What the payments were for
- Consulting fees$6,49125%
- Speaking & faculty fees$5,70222%
- Travel & lodging$4,28817%
- Food & beverage$9,01235%
- Education$200%
- Gifts$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 31 | $12,247 |
| Embecta Corp. | 6 | $3,126 |
| Mannkind Corporation | 14 | $2,033 |
| Novo Nordisk | 25 | $961 |
| BD | 2 | $821 |
| Tandem Diabetes Care, Inc. | 13 | $775 |
| Boston Scientific | 7 | $584 |
| Teva Pharmaceuticals USA, Inc. | 5 | $408 |
| Dexcom, Inc. | 8 | $396 |
| Abbott | 9 | $383 |
| Lilly USA, LLC | 11 | $381 |
| Xeris Pharmaceuticals, Inc. | 5 | $344 |
| AstraZeneca(2 entities) | 5 | $317 |
| BETA Bionics, Inc. | 3 | $265 |
| Boehringer Ingelheim | 2 | $245 |
| Insulet Corporation | 2 | $237 |
| Cequr Corporation | 4 | $233 |
| Bayer | 4 | $233 |
| Inari Medical, Inc. | 3 | $221 |
| Medtronic | 2 | $166 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $160 |
| Corcept Therapeutics | 3 | $132 |
| Corium, LLC | 1 | $130 |
| Lundbeck LLC | 1 | $125 |
| Biohaven Pharmaceuticals, Inc. | 1 | $117 |
| Daiichi Sankyo Inc. | 1 | $113 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $108 |
| AbbVie | 2 | $98 |
| Zealand Pharma US, Inc. | 4 | $81 |
| Phathom Pharmaceuticals, Inc. | 1 | $68 |
| Verona Pharma, Inc. | 1 | $62 |
| Averitas Pharma Inc. | 2 | $62 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$5,376
- AFREZZA$1,549
- iLet Bionic Pancreas$760
- iLet Insulin Infusion Kit Inset$253
- iLet Insulin Infusion Kit Contact Detach$253
- JARDIANCE$245
- Omnipod$175
- MINIMED 780G$150
- WATCHMAN FLX$140
- AUSTEDO$139
- FreeStyle Libre Pro$133
- Azstarys$130
- DEXCOM G7 GSS (161)$125
- VYEPTI$125
- BREZTRI$125
- t-slim insulin pump$125
- t:slim X2 Insulin Pump with Control-IQ$122
- Kerendia$121
- DEXCOM G6 TRANSMITTER$121
- Ozempic$117
How this compares
$25,633 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 206 | $166,594 |
| OzempicSemaglutide | 138 | $144,444 |
| MounjaroTirzepatide | 93 | $111,326 |
| TrulicityDulaglutide | 106 | $103,047 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 99 | $101,170 |
| V-Go 40Sub-Q Insulin Device, 40 Unit | 101 | $52,736 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 66 | $46,122 |
| Humulin R U-500Insulin Regular, Human | 24 | $33,387 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $30,183 |
| LyumjevInsulin Lispro-Aabc | 34 | $25,407 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 25 | $22,685 |
| V-Go 20Sub-Q Insulin Device, 20 Unit | 36 | $21,004 |
| XareltoRivaroxaban | 26 | $20,668 |
| EliquisApixaban | 27 | $18,948 |
| HumalogInsulin Lispro | 105 | $18,794 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $381 | $258,573338 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog | $961 | $175,247204 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $245 | $172,423218 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $12,247 | $101,17099 claims |
| AstraZenecaFarxiga | $317 | $10,77615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Everett
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
- Patricia HabdasPittsburgh$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.